Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Science (New York, N.Y.)|November 5, 2011
The pace of shifting climate in marine and terrestrial ecosystemsMichael T Burrows, David S Schoeman, Lauren B Buckley, et al.
Leukemia|July 18, 2021
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202Amy S Ruppert, Allison M Booth, Wei Ding, et al.
Blood Advances|December 20, 2024
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignanciesMatthew S Davids, Danielle M Brander, Yesid Alvarado-Valero, et al.
Lancet (London, England)|June 9, 2023
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 studyTanya Siddiqi, David G Maloney, Saad S Kenderian, et al.
Blood Advances|January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLLInhye E Ahn, Danielle M Brander, Yue Ren, et al.
Transplantation and Cellular Therapy|June 13, 2025
Clinical practice recommendations on the role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy in patients with chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular TherapyMohamed A Kharfan-Dabaja, Ambuj Kumar, Javier Pinilla-Ibarz, et al.
The Lancet. Haematology|June 19, 2019
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trialMatthew S Davids, Danielle M Brander, Haesook T Kim, et al.
Blood Cancer Journal|February 5, 2025
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestryCecilia Bonolo de Campos, Chantal E McCabe, Laura A Bruins, et al.
The Science of the Total Environment|July 24, 2024
The time for ambitious action is now: Science-based recommendations for plastic chemicals to inform an effective global plastic treatySusanne M Brander, Kala Senathirajah, Marina O Fernandez, et al.
Haematologica|February 9, 2018
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysisAnthony R Mato, Chadhi Nabhan, Meghan C Thompson, et al.
Pageof 10